Efficacy and Tolerability of Pantovigar® Vegan in Female Subjects With Diffuse Hair Loss
1 other identifier
interventional
39
1 country
1
Brief Summary
The objective of this study is to assess the hair growth efficacy of a Food for Special Medicinal Purposes (FSMP) Pantovigar® vegan after 3 and 6 months of intake.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2021
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 13, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2022
CompletedFirst Submitted
Initial submission to the registry
June 21, 2023
CompletedFirst Posted
Study publicly available on registry
July 13, 2023
CompletedJuly 13, 2023
July 1, 2023
9 months
June 21, 2023
July 3, 2023
Conditions
Outcome Measures
Primary Outcomes (2)
Self-assessment questionnaire for product acceptance by subjects
Months 3
Self-assessment questionnaire for product acceptance by subjects
Months 6
Secondary Outcomes (8)
Effect on hair growth assessed by phototrichogram analysis
Baseline up to month 6
Change from baseline of blood parameters: Ferritin
Baseline up to month 6
Change from baseline of several blood parameters: Vitamin B1
Baseline up to month 6
Change from baseline of several blood parameters: Biotin
Baseline up to month 6
Change from baseline of several blood parameters: Folic acid
Baseline up to month 6
- +3 more secondary outcomes
Study Arms (1)
Pantovigar vegan treatment
EXPERIMENTALInterventions
Oral application of 1 capsule three times a day (morning, noon, evening) for 6 months
Eligibility Criteria
You may qualify if:
- Diffuse hair loss
- Modified Savin Score I to III
- Hair length of at least 2 cm
You may not qualify if:
- Pathological hair loss (like alopecia areata, universalis or totalis; scarring alopecias; androgenic alopecia; inflammatory conditions of the scalp)
- Symptomatic diffuse alopecia due to pathological low iron concentration or thyroid gland disorder
- Acute telogen effluvium
- Recent or concomitant treatment with any drugs that may cause hair loss
- Concomitant diseases that can cause hair loss
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
proDerm
Schenefeld, 22869, Germany
Study Officials
- STUDY DIRECTOR
Merz Medical Expert
Merz Therapeutics
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 21, 2023
First Posted
July 13, 2023
Study Start
September 13, 2021
Primary Completion
May 31, 2022
Study Completion
May 31, 2022
Last Updated
July 13, 2023
Record last verified: 2023-07
Data Sharing
- IPD Sharing
- Will not share